MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-22-2026
Johnson & Johnson Accounts Receivables 2011-2026 | JNJ
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Johnson & Johnson
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.2 B | 14.8 B | 14.9 B | 15.3 B | 13.6 B | - | 14.5 B | 14.1 B | 13.5 B | 10.7 B | - | 11 B | 11.7 B | 11.3 B | 9.77 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.2 B | 9.77 B | 13.3 B |
Quarterly Accounts Receivables Johnson & Johnson
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.7 B | 17.6 B | 17.8 B | 16 B | 16.2 B | 15.8 B | 14.9 B | 14.8 B | 16.8 B | 16.4 B | 16.2 B | 15.9 B | - | 15.6 B | 13.6 B | 14.9 B | 14.9 B | 14.9 B | - | 14.6 B | 14.6 B | 14.9 B | 14.5 B | 14.5 B | 14.5 B | 14.5 B | 14.1 B | 14.1 B | 14.1 B | 14.1 B | 13.5 B | 13.5 B | 13.5 B | 13.5 B | 10.7 B | 11.8 B | 12.1 B | 11.4 B | - | 11.4 B | 12 B | 11.5 B | 11 B | 11 B | 11 B | 11 B | 11.7 B | 11.7 B | 11.7 B | 11.7 B | 11.3 B | 11.3 B | 11.3 B | 11.3 B | 9.77 B | 10.6 B | 11 B | 10.9 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.8 B | 9.77 B | 13.5 B |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amphastar Pharmaceuticals
AMPH
|
144 M | $ 21.66 | 1.14 % | $ 1.01 B |  USA |
 |
I-Mab
IMAB
|
130 M | - | - | $ 866 M |  China |
 |
Aptorum Group Limited
APM
|
62.2 K | $ 0.9 | -0.2 % | $ 6.62 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
98.7 M | $ 22.33 | 1.66 % | $ 3.7 B | USA |
 |
Esperion Therapeutics
ESPR
|
140 M | $ 1.94 | 1.31 % | $ 403 M | USA |
 |
Advaxis
ADXS
|
234 K | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
200 K | - | 1.93 % | $ 17.4 M | USA |
 |
Heron Therapeutics
HRTX
|
89.6 M | $ 1.18 | -0.84 % | $ 197 M | USA |
 |
ImmuCell Corporation
ICCC
|
3.42 M | $ 8.26 | -1.07 % | $ 74.6 M | USA |
 |
Jaguar Health
JAGX
|
1.52 M | $ 0.29 | -25.25 % | $ 676 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
312 K | - | -2.5 % | $ 5.88 M | USA |
 |
Aptinyx
APTX
|
257 K | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
57 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
1 M | - | 17.91 % | $ 11.1 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
2.59 M | $ 19.09 | -2.75 % | $ 1.03 B |  Britain |
 |
Aquestive Therapeutics
AQST
|
17.8 M | $ 4.11 | 0.61 % | $ 439 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
146 M | $ 23.18 | -0.34 % | $ 2.95 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
24 M | $ 1.43 | -0.7 % | $ 381 M | Britain |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
38.4 M | $ 240.72 | 4.09 % | $ 4.4 B | USA |
 |
Eli Lilly and Company
LLY
|
17.8 B | $ 874.81 | -1.06 % | $ 785 B | USA |
 |
BioDelivery Sciences International
BDSI
|
56.9 M | - | -4.8 % | $ 255 M | USA |